{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:51:04Z","timestamp":1792061464000,"version":"4.4.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This essay examines the costs of regulatory failure by highlighting the serious neuropsychiatric risks associated with finasteride, a popular hair-loss medication that can cause long-lasting depression and suicidal thoughts. In the United States, illustrative estimates suggest that hundreds of thousands of users may experience depression, over a thousand may die by suicide, and the associated societal costs may approach several billion dollars annually. The article criticizes the FDA and the pharmaceutical industry for failing to conduct or require thorough post-marketing safety studies despite early warning signs.<\/jats:p>\n                  <jats:p>The author concludes that public health must take precedence over corporate interests and shareholder duties. To prevent future similar events, the article proposes regulatory reform that mandates ongoing surveillance. Regulators must require manufacturers to commit to continuous safety monitoring and formal studies after a medication is approved. Regulators must enforce these post-approval study requirements with clear timelines, rather than relying on industry self-discipline, to rebuild public trust and protect citizens from drug safety failures.<\/jats:p>","DOI":"10.1093\/pubmed\/fdag077","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:24:25Z","timestamp":1792059865000},"source":"Crossref","is-referenced-by-count":0,"title":["Finasteride and depression: the high cost of failed regulation"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3199-9641","authenticated-orcid":false,"given":"Mayer","family":"Brezis","sequence":"first","affiliation":[{"name":"Braun School of Public Health and Community Medicine, Faculty of Medicine, Hebrew University\u2013Hadassah , Ein Kerem, P.O. Box 12272, Jerusalem 9112102 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026101506241860100_ref1","doi-asserted-by":"publisher","first-page":"25nr15862","DOI":"10.4088\/JCP.25nr15862","article-title":"Failing public health again? Analytical review of depression and suicidality from finasteride","volume":"86","author":"Brezis","year":"2025","journal-title":"J Clin Psychiatry"},{"key":"2026101506241860100_ref2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1943-278X.2010.00009.x","article-title":"Estimating the population of survivors of suicide: seeking an evidence base","volume":"41","author":"Berman","year":"2011","journal-title":"Suicide Life Threat Behav"},{"key":"2026101506241860100_ref3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg","year":"2021","journal-title":"PharmacoEconomics."},{"key":"2026101506241860100_ref4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/brainsci16040394","article-title":"Signal detection of depression and suicidality associated with finasteride and dutasteride: updated pharmacovigilance evidence and recommendations for comprehensive psychiatric assessment","volume":"16","author":"Chiappini","year":"2026","journal-title":"Brain Sci"},{"key":"2026101506241860100_ref5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41397-026-00420-6","article-title":"Finasteride, pharmacogenomics, and suicide risk: a public health concern","volume":"26","author":"Perezcano","year":"2026","journal-title":"Pharmacogenomics J"},{"key":"2026101506241860100_ref6","volume-title":"Finasteride: Review of Safety Data and Expert Advice on Management of Risks (Public Assessment Report)","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"2026101506241860100_ref7","volume-title":"M\u00e9dicaments contenant du finast\u00e9ride ou du dutast\u00e9ride: conclusions concernant le risque d\u2019id\u00e9es suicidaires","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament (ANSM)","year":"2025"},{"key":"2026101506241860100_ref8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41443-023-00750-0","article-title":"Beliefs and counseling practices among dermatologists regarding sexual and other adverse effects of finasteride","volume":"37","author":"Irwig","year":"2023","journal-title":"Int J Impot Res"},{"key":"2026101506241860100_ref9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.5534\/wjmh.190046","article-title":"Risk of depression after 5 alpha reductase inhibitor medication: meta-analysis","volume":"38","author":"Kim","year":"2020","journal-title":"World J Mens Health"},{"key":"2026101506241860100_ref10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.euf.2024.04.009","article-title":"Association of 5\u03b1-reductase inhibitors with depression and suicide: a mini systematic review and meta-analysis","volume":"10","author":"Uleri","year":"2024","journal-title":"Eur Urol Focus"},{"key":"2026101506241860100_ref11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/00325481.2026.2633464","article-title":"Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement","volume":"138","author":"Nguyen","year":"2026","journal-title":"Postgrad Med"},{"key":"2026101506241860100_ref12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/phar.1925","article-title":"Risk of incident antidepressant-treated depression associated with use of 5\u03b1-reductase inhibitors compared with use of \u03b1-blockers in men with benign prostatic hyperplasia: a population-based study using the clinical practice research datalink","volume":"37","author":"Hagberg","year":"2017","journal-title":"Pharmacotherapy."},{"key":"2026101506241860100_ref13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/JU.0000000000001079","article-title":"Lack of association between 5\u03b1-reductase inhibitors and depression","volume":"204","author":"Dyson","year":"2020","journal-title":"J Urol"},{"key":"2026101506241860100_ref14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/PSY.0000000000000784","article-title":"The association of 5\u03b1-reductase inhibitor with suicidality","volume":"82","author":"Kim","year":"2020","journal-title":"Psychosom Med"},{"key":"2026101506241860100_ref15","doi-asserted-by":"publisher","first-page":"e0265169","DOI":"10.1371\/journal.pone.0265169","article-title":"Depression risk associated with the use of 5\u03b1-reductase inhibitors versus \u03b1-blockers: a retrospective cohort study in South Korea","volume":"17","author":"Yeon","year":"2022","journal-title":"PloS One"},{"key":"2026101506241860100_ref16","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2026.2708396","article-title":"Finasteride prescribed for hair loss consistently leads to depression. Comment on \u2018Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement\u2019","author":"Brezis","year":"2026","journal-title":"Postgrad Med"},{"key":"2026101506241860100_ref17","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1176\/appi.ajp.2007.07050775","article-title":"The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses","volume":"164","author":"Leon","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2026101506241860100_ref18","article-title":"Warning regarding a Mendelian randomization study of finasteride (comment)","author":"Brezis","year":"2026","journal-title":"PubPeer"},{"key":"2026101506241860100_ref19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000497362","article-title":"Post-finasteride syndrome: an induced delusional disorder with the potential of a mass psychogenic illness?","volume":"5","author":"Tr\u00fceb","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"2026101506241860100_ref20","first-page":"220","article-title":"Neuropsychiatric reactions to finasteride: nocebo or true effect?","volume":"14","author":"Brezis","year":"2023","journal-title":"J Basic Clin Pharma"},{"key":"2026101506241860100_ref21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"2026101506241860100_ref22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1056\/NEJMra1907805","article-title":"Placebo and nocebo effects","volume":"382","author":"Colloca","year":"2020","journal-title":"N Engl J Med"},{"key":"2026101506241860100_ref23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/archdermatol.2010.256","article-title":"Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review","volume":"146","author":"Mella","year":"2010","journal-title":"Arch Dermatol"},{"key":"2026101506241860100_ref24","first-page":"9","article-title":"Hair regrowth treatment efficacy and resistance in androgenetic alopecia: a systematic review and continuous Bayesian network meta-analysis","author":"Feldman","year":"2023","journal-title":"Front Med"},{"key":"2026101506241860100_ref25","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1080\/13548506.2023.2242049","article-title":"Psychosocial impact of androgenetic alopecia on men: a systematic review and meta-analysis","volume":"29","author":"Frith","year":"2024","journal-title":"Psychol Health Med"},{"key":"2026101506241860100_ref26","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.3390\/jcm13154534","article-title":"Physical treatments and therapies for androgenetic alopecia","volume":"13","author":"Lama","year":"2024","journal-title":"J Clin Med"},{"key":"2026101506241860100_ref27","volume-title":"Finasteride- and Dutasteride-Containing Medicinal Products\u2014Referral","author":"European Medicines Agency","year":"2024"},{"key":"2026101506241860100_ref28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/9781119413431.ch27","article-title":"Data mining and other informatics approaches to pharmacoepidemiology","author":"Bate","year":"2019","journal-title":"Pharmacoepidemiology"},{"key":"2026101506241860100_ref29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/14740338.2023.2203488","article-title":"There is no single gold standard study design (RCTs are not the gold standard)","volume":"22","author":"Gerstman","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"2026101506241860100_ref30","doi-asserted-by":"crossref","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"2026101506241860100_ref31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40264-023-01325-0","article-title":"Use of electronic health record data for drug safety signal identification: a scoping review","volume":"46","author":"Davis","year":"2023","journal-title":"Drug Saf"},{"key":"2026101506241860100_ref32","volume-title":"They Wanted a Quick Fix for Hair Loss. Instead, These Young Men Got Sick","author":"Winkler","year":"2025"},{"key":"2026101506241860100_ref33","volume-title":"Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment\u2014Guidance for Industry","author":"US Food and Drug Administration","year":"2005"},{"key":"2026101506241860100_ref34","volume-title":"Rethinking Medications: Truth, Power, and the Drugs You Take","author":"Avorn","year":"2025"},{"key":"2026101506241860100_ref35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/sj.clpt.6100233","article-title":"An evaluation of computer-aided disproportionality analysis for post-marketing signal detection","volume":"82","author":"Lehman","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2026101506241860100_ref36","volume-title":"Product Safety & Quality\u2014Patient Safety","author":"Merck"},{"key":"2026101506241860100_ref37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2202\/1553-3832.1198","volume-title":"The (Legal) Pains of Vioxx: Why Product Liability Can Make Products More Dangerous","author":"Ben-Shahar","year":"2006"}],"container-title":["Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpubhealth\/advance-article-pdf\/doi\/10.1093\/pubmed\/fdag077\/71962607\/fdag077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpubhealth\/advance-article-pdf\/doi\/10.1093\/pubmed\/fdag077\/71962607\/fdag077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:24:28Z","timestamp":1792059868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpubhealth\/advance-article\/doi\/10.1093\/pubmed\/fdag077\/8917267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1093\/pubmed\/fdag077","relation":{},"ISSN":["1741-3842","1741-3850"],"issn-type":[{"value":"1741-3842","type":"print"},{"value":"1741-3850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"fdag077"}}